Sartorius (SRT3) PT Set at €141.00 by Warburg Research

Sartorius (FRA:SRT3) has been given a €141.00 ($163.95) price objective by investment analysts at Warburg Research in a note issued to investors on Friday. The firm currently has a “buy” rating on the stock. Warburg Research’s price target would indicate a potential upside of 17.60% from the company’s current price.

A number of other brokerages also recently issued reports on SRT3. HSBC set a €99.00 ($115.12) price objective on Sartorius and gave the company a “sell” rating in a research note on Thursday, October 18th. Berenberg Bank set a €110.00 ($127.91) price objective on Sartorius and gave the company a “neutral” rating in a research note on Thursday, October 18th. Commerzbank set a €101.00 ($117.44) price objective on Sartorius and gave the company a “sell” rating in a research note on Friday, October 19th. Nord/LB set a €80.00 ($93.02) price objective on Sartorius and gave the company a “sell” rating in a research note on Monday, October 29th. Finally, Kepler Capital Markets set a €107.00 ($124.42) price target on Sartorius and gave the stock a “sell” rating in a research note on Wednesday, October 24th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. Sartorius has a consensus rating of “Hold” and a consensus price target of €107.94 ($125.52).

FRA:SRT3 traded down €6.60 ($7.67) during trading on Friday, reaching €119.90 ($139.42). The company’s stock had a trading volume of 29,855 shares. Sartorius has a 12 month low of €71.00 ($82.56) and a 12 month high of €124.70 ($145.00).

About Sartorius

Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.

Featured Story: Are Wall Street analysts’ stock ratings worth following?

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply